A Phase 3 interventional study of Obinutuzumab and Cyclophosphamide in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 183 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-11.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. obinutuzumab · Lymphoma, Non-Hodgkin.
Among the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, this one has the largest enrollment, is the only one that started in 2011, is one of 2 in phase 3, and was the 3rd registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →3 of the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin are open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
New York Medical College · Sites in United States
Ages 3–31
Henan Cancer Hospital
Ages 18+
By country, each count listing its studies:
obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 2
First in 2008; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,401 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 41 across the 15 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one has the largest enrollment of the 49 interventional ones that give a count, is one of 6 that started in 2011, is one of 11 in phase 3, and was the 22nd registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
3 of the studies testing obinutuzumab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02393157New York Medical CollegeObinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | 2026-12 |
| NCT04077723Hoffmann-La RocheA Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | 2026-12-28 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response [CR] or partial response [PR]) will undergo a maintenance period continuing on the randomized antibody treatment alone every 2 months until disease progression for a total of 2 years. Anticipated time on study treatment is up to approximately 2.5 years. After maintenance or observation, participants will be followed for 5 years until progression. After progression, participants will be followed for new anti-lymphoma therapy and overall survival until the end of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Bendamustine · Drug: Rituximab
Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
Drug: Obinutuzumab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Bendamustine
Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
Also known as: GA101; RO5072759
Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.
Also known as: MabThera/Rituxan
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
Time frame: Baseline up to data cut-off (up to approximately 4 years and 7 months)
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
Time frame: Baseline up to final analysis (up to 10 years)
Progression-Free Survival in the Overall Study Population, Investigator-Assessed
Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed
Progression-free survival in the participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. In the first 170 patients with follicular lymphoma, an FDG-PET was mandatory where a PET scanner was available.
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)
Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Overall Response (Follicular Lymphoma Population), Investigator-Assessed
Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with and without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Overall Response (OR) = CR + PR.
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Overall Response (Overall Study Population), Investigator-Assessed
Overall response in the overall study population was defined as percentage of participants with partial response (PR) or complete response (CR) determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without positron emission tomography (PET). CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%; Overall Response (OR) = CR + PR.
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Follicular Lymphoma Population), Investigator-Assessed
Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Overall Study Population), Investigator-Assessed
Percentage of participants with complete response in the overall study population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Overall Response (Follicular Lymphoma Population), IRC-Assessed
Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Overall Response (OR) = CR + PR.
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Overall Response (Overall Study Population), IRC-Assessed
Overall response in the overall study population was defined as percentage of participants with PR or CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%; Overall Response (OR) = CR + PR.
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Follicular Lymphoma Population), IRC-Assessed
Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Overall Study Population), IRC-Assessed
Percentage of participants with complete response in the overall study population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
Time frame: Baseline up to end of induction period (up to approximately 7 months)]
Overall Survival (Follicular Lymphoma Population)
Overall survival in the follicular lymphoma population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.
Time frame: Baseline up to 10 years
Overall Survival (Overall Study Population)
Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Event-Free Survival (Follicular Lymphoma Population)
Event-free survival in the follicular lymphoma population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with an event.
Time frame: Baseline up to 10 years
Event-Free Survival (Overall Study Population)
Event-free survival in the overall study population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event.
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Disease-Free Survival (Follicular Lymphoma Population)
Disease-free survival in the follicular lymphoma population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma (RRCML). Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Reported is the percentage of participants with event.
Time frame: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)
Disease-Free Survival (Overall Study Population)
Disease-free survival in the overall study population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Reported is the percentage of participants with event.
Time frame: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)
Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed
DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.
Time frame: From first occurrence of documented CR or PR to data cut-off (up to approximately 5 years and 2 months)
Duration of Response (DOR) (Overall Study Population), Investigator-Assessed
DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.
Time frame: From first occurrence of documented CR or PR to data cut-off (up to approximately 4 years and 7 months)
Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)
Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.
Time frame: Baseline up to 10 years
Time to Next Anti-Lymphoma Treatment (Overall Study Population)
Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Percentage of Participants With Adverse Events
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Baseline up to 10 years
Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)
FACT-G consists of the following 4 FACT-Lym sub-questionnaires: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24) and Functional Well-being (range: 0-28). Higher scores indicate better outcomes. A positive change from baseline indicates improvement. Maint = Maintenance period.
Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)
The FACT-Lym TOI Score for the follicular lymphoma population was derived from the following 3 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym TOI Score is the sum of the 3 individual subscales (range 0-116). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.
Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)
The FACT-Lym Individual Subscale Lymphoma Score for the follicular lymphoma population was derived from the Lymphoma subscale questionnaire (range: 0-60). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.
Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)
The FACT-Lym Total Score for the follicular lymphoma population was derived from the following 5 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24),Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym Total Score is the sum of all 5 individual subscales (range 0-168). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.
Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase
The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs.
Time frame: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase
The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1 Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs. Completion includes completion visit and early termination visit.
Time frame: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase
The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs in data categories. Completion includes completion visit and early termination visit.
Time frame: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 after Day 1 of last induction cycle, Follow-up: every year for up to data cut-off (up to 5 years and 2 months)
The study was conducted at 177 centers in 18 countries.
| Milestone | Rituximab+Chemotherapy - Induction Period | Obinutuzumab+Chemotherapy - Induction Period | Rituximab+Chemotherapy - Maintenance Period | Obinutuzumab+Chemotherapy - Maintenance Period | Rituximab+Chemotherapy - Observation Period | Obinutuzumab+Chemotherapy - Observation Period | Rituximab+Chemotherapy - Follow-Up Period | Obinutuzumab+Chemotherapy - Follow-Up Period |
|---|---|---|---|---|---|---|---|---|
| Started | 699 | 702 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 641 | 646 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 58 | 56 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 23 | 26 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 15 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomised but not treated | 4 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Rituximab+Chemotherapy - Induction Period | Obinutuzumab+Chemotherapy - Induction Period | Rituximab+Chemotherapy - Maintenance Period | Obinutuzumab+Chemotherapy - Maintenance Period | Rituximab+Chemotherapy - Observation Period | Obinutuzumab+Chemotherapy - Observation Period | Rituximab+Chemotherapy - Follow-Up Period | Obinutuzumab+Chemotherapy - Follow-Up Period |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 612 | 624 | 12 | 11 | 0 | 0 |
| Completed | 0 | 0 | 451 | 475 | 12 | 10 | 0 | 0 |
| Not completed | 0 | 0 | 161 | 149 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 53 | 66 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 5 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 0 | 4 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 4 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 14 | 19 | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 72 | 40 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 7 | 5 | 0 | 0 | 0 | 0 |
| Milestone | Rituximab+Chemotherapy - Induction Period | Obinutuzumab+Chemotherapy - Induction Period | Rituximab+Chemotherapy - Maintenance Period | Obinutuzumab+Chemotherapy - Maintenance Period | Rituximab+Chemotherapy - Observation Period | Obinutuzumab+Chemotherapy - Observation Period | Rituximab+Chemotherapy - Follow-Up Period | Obinutuzumab+Chemotherapy - Follow-Up Period |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 554 | 602 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 324 | 367 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 230 | 235 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 27 | 30 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 15 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 9 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 21 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 15 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 126 | 106 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 32 |
| Withdrew: No reason provided | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed | 24.0 | 16.8 |
Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed | 40.6 | 34.3 |
Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Progression-Free Survival in the Overall Study Population, Investigator-Assessed | 41.5 | 34.8 |
Progression-free survival in the participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. In the first 170 patients with follicular lymphoma, an FDG-PET was mandatory where a PET scanner was available.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed | 23.5 | 18.0 |
Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC) | 24.6 | 18.4 |
Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with and without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Overall Response (OR) = CR + PR.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 86.4 | 88.2 |
| With PET | 81.2 | 85.5 |
Overall response in the overall study population was defined as percentage of participants with partial response (PR) or complete response (CR) determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without positron emission tomography (PET). CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%; Overall Response (OR) = CR + PR.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 85.7 | 87.3 |
| With PET | 81.8 | 85.4 |
Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 24.1 | 18.6 |
| With PET | 56.7 | 62.0 |
Percentage of participants with complete response in the overall study population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 23.3 | 18.4 |
| With PET | 57.0 | 61.1 |
Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Overall Response (OR) = CR + PR.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 88.0 | 91.3 |
| With PET | 85.2 | 88.6 |
Overall response in the overall study population was defined as percentage of participants with PR or CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%; Overall Response (OR) = CR + PR.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 86.7 | 89.9 |
| With PET | 83.3 | 87.2 |
Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 26.8 | 28.5 |
| With PET | 59.7 | 71.4 |
Percentage of participants with complete response in the overall study population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 26.3 | 27.1 |
| With PET | 59.4 | 69.5 |
Overall survival in the follicular lymphoma population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Overall Survival (Follicular Lymphoma Population) | 14.3 | 12.6 |
Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Overall Survival (Overall Study Population) | 10.2 | 8.4 |
Event-free survival in the follicular lymphoma population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with an event.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Event-Free Survival (Follicular Lymphoma Population) | 42.9 | 35.8 |
Event-free survival in the overall study population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Event-Free Survival (Overall Study Population) | 30.6 | 22.6 |
Disease-free survival in the follicular lymphoma population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma (RRCML). Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Reported is the percentage of participants with event.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Disease-Free Survival (Follicular Lymphoma Population) | 27.9 | 26.3 |
Disease-free survival in the overall study population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Reported is the percentage of participants with event.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Disease-Free Survival (Overall Study Population) | 14.9 | 11.2 |
DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed | 39.3 | 33.3 |
DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Duration of Response (DOR) (Overall Study Population), Investigator-Assessed | 25.5 | 18.7 |
Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population) | 34.8 | 26.6 |
Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.
| percentage of participants with event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Time to Next Anti-Lymphoma Treatment (Overall Study Population) | 21.6 | 15.7 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| percentage of participants | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Percentage of Participants With Adverse Events | 99.6 | 99.9 |
FACT-G consists of the following 4 FACT-Lym sub-questionnaires: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24) and Functional Well-being (range: 0-28). Higher scores indicate better outcomes. A positive change from baseline indicates improvement. Maint = Maintenance period.
| units on a scale | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Physical Well-being (PW), Baseline | 23.36 ± 4.77 | 23.14 ± 4.85 |
| PW Change, Cycle 3, Day 1 | -0.91 ± 4.54 | -0.21 ± 4.59 |
| PW Change, End Induction | -0.06 ± 4.83 | 0.56 ± 5.14 |
| PW Change, Maint Month 2 | 0.83 ± 4.76 | 1.42 ± 5.09 |
| PW Change, Maint Month 12 | 1.14 ± 4.29 | 1.34 ± 4.74 |
| PW Change, End Maint | 0.88 ± 4.54 | 1.33 ± 5.00 |
| Social/Family Well-being , Baseline | 22.84 ± 4.92 | 23.28 ± 4.77 |
| S/FW Change, Cycle 3 Day 1 | -0.52 ± 4.03 | -0.67 ± 3.92 |
| S/FW Change, End Induction | -0.46 ± 4.77 | -0.56 ± 5.00 |
| S/FW Change, Maint Month 2 | -0.39 ± 4.72 | -0.67 ± 4.68 |
| S/FW Change, Maint Month 12 | -0.61 ± 5.56 | -0.97 ± 5.34 |
| S/FW Change, End Maint | -0.93 ± 5.67 | -0.71 ± 5.54 |
| Emotional Well-being (EW), Baseline | 17.64 ± 4.19 | 17.87 ± 4.13 |
| EW Change, Cycle 3 Day 1 | 1.49 ± 3.40 | 1.35 ± 3.35 |
| EW Change, End Induction | 1.16 ± 3.90 | 1.14 ± 3.87 |
| EW Change, Maint Month 2 | 1.77 ± 3.88 | 1.49 ± 4.16 |
| EW Change, Maint Month 12 | 1.45 ± 3.92 | 1.46 ± 3.88 |
| EW Change, End Maint | 1.43 ± 3.98 | 1.49 ± 3.99 |
| Functional Well-being (FW), Baseline | 18.66 ± 6.19 | 18.76 ± 5.98 |
| FW Change, Cycle 3 Day 1 | -0.30 ± 5.30 | -0.07 ± 5.24 |
| FW Change, End Induction | 0.44 ± 5.63 | 0.93 ± 5.85 |
| FW Change, Maint Month 2 | 1.04 ± 5.31 | 1.25 ± 6.02 |
| FW Change, Maint Month 12 | 1.84 ± 5.54 | 1.65 ± 5.95 |
| FW Change, End Maint | 1.40 ± 6.12 | 1.72 ± 6.16 |
The FACT-Lym TOI Score for the follicular lymphoma population was derived from the following 3 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym TOI Score is the sum of the 3 individual subscales (range 0-116). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.
| units on a scale | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| TOI Score, Baseline | 86.61 ± 18.16 | 86.94 ± 18.05 |
| TOI Score Change, Cycle 3 Day 1 | 0.46 ± 15.03 | 2.18 ± 15.95 |
| TOI Score Change, End Induction | 2.91 ± 17.00 | 4.57 ± 16.71 |
| TOI Score Change, Maint M2 | 6.22 ± 16.16 | 7.17 ± 16.57 |
| TOI Score Change, Maint M12 | 7.61 ± 15.62 | 7.20 ± 16.75 |
| TOI Score Change, End Maint | 6.23 ± 17.06 | 7.44 ± 16.96 |
The FACT-Lym Individual Subscale Lymphoma Score for the follicular lymphoma population was derived from the Lymphoma subscale questionnaire (range: 0-60). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.
| units on a scale | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Lymphoma, Baseline | 45.01 ± 9.37 | 45.54 ± 9.29 |
| Lymphoma Change, Cycle 3 Day 1 | 2.04 ± 7.18 | 2.71 ± 7.46 |
| Lymphoma Change, End Induction | 2.99 ± 8.63 | 3.01 ± 8.36 |
| Lymphoma Change, Maint Month 2 | 4.80 ± 8.29 | 4.52 ± 8.32 |
| Lymphoma Change, Maint Month 12 | 4.93 ± 8.34 | 4.27 ± 8.31 |
| Lymphoma Change, End Maint | 4.31 ± 8.81 | 4.57 ± 8.54 |
The FACT-Lym Total Score for the follicular lymphoma population was derived from the following 5 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24),Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym Total Score is the sum of all 5 individual subscales (range 0-168). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.
| units on a scale | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Total Score, Baseline | 127.40 ± 22.43 | 128.42 ± 22.16 |
| Total Score Change, Cycle 3 Day 1 | 1.98 ± 17.01 | 3.21 ± 17.12 |
| Total Score Change, End Induction | 4.18 ± 19.75 | 5.10 ± 20.03 |
| Total Score Change, Maint Month 2 | 8.40 ± 19.16 | 8.13 ± 19.80 |
| Total Score Change, Maint Month 12 | 8.87 ± 19.31 | 7.90 ± 19.55 |
| Total Score Change, End Maint | 7.43 ± 19.88 | 8.80 ± 20.57 |
The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs.
| units on a scale | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Baseline Induction | 0.80 ± 0.24 | 0.81 ± 0.21 |
| Change Baseline, Cycle 3 Day 1 | 0.03 ± 0.21 | 0.03 ± 0.20 |
| Change Baseline, Induction Compl | 0.04 ± 0.23 | 0.03 ± 0.22 |
| Change Baseline, Maint/Obs Month 2 | 0.05 ± 0.23 | 0.06 ± 0.22 |
| Change from Baseline, Maint/Obs Month 12 | 0.00 ± 0.00 | -0.20 ± NA |
| Change Baseline, Maint/Obs Completion | — | -0.10 ± NA |
The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1 Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs. Completion includes completion visit and early termination visit.
| units on a scale | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Change Baseline, Maint/Obs Month 2 | 0.04 ± 0.34 | 0.04 ± 0.14 |
| Change Baseline, Maint/Obs Month 12 | 0.06 ± 0.24 | 0.06 ± 0.21 |
| Change Baseline, Maint/Obs Completion | 0.03 ± 0.23 | 0.05 ± 0.23 |
The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs in data categories. Completion includes completion visit and early termination visit.
| units on a scale | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Change Baseline, Follow-Up Month 36 | 0.05 ± 0.24 | 0.06 ± 0.23 |
| Change Baseline, Follow-Up Month 48 | 0.05 ± 0.20 | 0.06 ± 0.23 |
Collected over Baseline up to 10 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab+Chemotherapy | 111/692 (16%) | 309/692 (44.7%) | 675/692 (97.5%) |
| Obinutuzumab+Chemotherapy | 104/698 (14.9%) | 361/698 (51.7%) | 690/698 (98.9%) |
| Event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| PNEUMONIAInfections and infestations | 43/692 | 51/698 |
| PYREXIAGeneral disorders | 23/692 | 37/698 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 23/692 | 36/698 |
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 19/692 | 36/698 |
| NEUTROPENIABlood and lymphatic system disorders | 33/692 | 28/698 |
| SEPSISInfections and infestations | 9/692 | 14/698 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 9/692 | 13/698 |
| DIARRHOEAGastrointestinal disorders | 7/692 | 11/698 |
| INFECTIONInfections and infestations | 10/692 | 6/698 |
| ABDOMINAL PAINGastrointestinal disorders | 6/692 | 10/698 |
| Event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 347/692 | 416/698 |
| NAUSEAGastrointestinal disorders | 338/692 | 354/698 |
| NEUTROPENIABlood and lymphatic system disorders | 307/692 | 348/698 |
| FATIGUEGeneral disorders | 277/692 | 275/698 |
| CONSTIPATIONGastrointestinal disorders | 221/692 | 249/698 |
| COUGHRespiratory, thoracic and mediastinal disorders | 185/692 | 221/698 |
| DIARRHOEAGastrointestinal disorders | 168/692 | 207/698 |
| PYREXIAGeneral disorders | 150/692 | 200/698 |
| VOMITINGGastrointestinal disorders | 151/692 | 182/698 |
| HEADACHENervous system disorders | 123/692 | 155/698 |
The intent-to treat (ITT) population was defined as all randomized participants grouped according to their randomized treatment arm regardless of what treatments were actually received.
| Age, Continuous(years) | Rituximab+Chemotherapy - Induction Period | Obinutuzumab+Chemotherapy - Induction Period | Total |
|---|---|---|---|
| Mean | 58.1 ± 12.3 | 58.9 ± 11.6 | 58.5 ± 11.9 |
| Sex: Female, Male(Participants) | Rituximab+Chemotherapy - Induction Period | Obinutuzumab+Chemotherapy - Induction Period | Total |
|---|---|---|---|
| Female | 374 | 365 | 739 |
| Male | 325 | 337 | 662 |
| Age Continuous in Follicular Lymphoma Sub-Population(years) | Rituximab+Chemotherapy - Induction Period | Obinutuzumab+Chemotherapy - Induction Period | Total |
|---|---|---|---|
| Mean | 57.7 ± 12.2 | 58.2 ± 11.5 | 57.9 ± 11.9 |
| Gender in Follicular Lymphoma Sub-Population(Participants) | Rituximab+Chemotherapy - Induction Period | Obinutuzumab+Chemotherapy - Induction Period | Total |
|---|---|---|---|
| Female | 321 | 318 | 639 |
| Male | 280 | 283 | 563 |
Showing the first 100 of 183 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2011 to primary completion in Feb 2016, 54 months.
Results were first posted in Jun 2017, 1 year 4 months after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 54 months is below that.
Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab